It is often said that the pharmaceutical industry only adapts in response to a crisis, and Vioxx might instigate the most dramatic of all changes. The withdrawal of Vioxx has exposed many scientific, clinical, regulatory and business issues that are fundamental to the industry's future. With the integrity of the drug-safety system under scrutiny, companies urgently need to understand how these problems arose, and how they can be prevented in future. One year on from Vioxx's withdrawal, Nature Reviews Drug Discovery asked people closely involved in the development and use of COX2-selective inhibitors what they think are the biggest lessons that can be learnt from this debacle.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Rights and permissions
About this article
Cite this article
Painful lessons. Nat Rev Drug Discov 4, 800–803 (2005). https://doi.org/10.1038/nrd1871
Issue Date:
DOI: https://doi.org/10.1038/nrd1871
